Intensive care medicine

Antirheumatic drugs

Biology

Hydroxychloroquine

Drug

Rheumatoid arthritis

Coronavirus disease 2019 (COVID-19)

Immunology

Antirheumatic Agents

Bioinformatics

Arthritis

Autoimmune disease

Infectious disease (medical specialty)

Internal medicine

Pharmacology

Medicine

Disease

Biomedicine & Pharmacotherapy

Rheumatoid arthritis (RA) is one of more than 100 types of arthritis. This chronic autoimmune disorder affects the lining of synovial joints in about 0.5% of people and may induce severe joints deformity and disability. RA impacts health life of people from all sexes and ages with more prevalence in elderly and women people. Significant improvement has been noted in the last two decades revealing the mechanisms of the development of RA, the improvement of the early diagnosis and the development of new treatment options. Non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids, and disease-modifying antirheumatic drugs (DMARDs) remain the most known treatments used against RA. However, not all patients respond well to these drugs and therefore, new solutions are of immense need to improve the disease outcomes. In the present review, we discuss and highlight the recent findings concerning the different classes of RA therapies including the conventional and modern drug therapies, as well as the recent emerging options including the phyto-cannabinoid and cell- and RNA-based therapies. A better understanding of their mechanisms and pathways might help find a specific target against inflammation, cartilage damage, and reduce side effects in arthritis.

Anti-rheumatoid drugs advancements: New insights into the molecular treatment of rheumatoid arthritis